⌕
Pacific Biosciences of California · PACB · Nasdaq
Tenet 40 · Weak
Compare
$1.84−6.12%At closeTenet 40 · Weak
$1.84−0.12 (−6.12%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Pacific Biosciences of California (PACB) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice
Business engineChoppy: revenue compounds ~5.2%/yr (FY21→FY25), net margin −341.5%. Worth your attention in FY25: Share count (+46.9%). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▲3.9%
160.0
FY21→FY25CAGR +5.2%/yr
Net income ($M)▼76.3%
−546.4
one-off year: see footnoteCAGR —
Free cash flow ($M)▲46.3%
−113.9
FY21→FY25CAGR —
Diluted EPS▼14.5%
−1.82
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+46.9%

204.1mn → 300.0mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.

Capex
$2.7M

−56.1% YoY in FY25 · 1.7% of revenue.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)160.0Revenue−114.2COGS45.8Gross profit−97.3R&D−141.5SG&A−553.9Op income7.5Tax & other−546.4Net income

-341¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.

Margin trend · direction beats level Gross Operating Net
503825130%FY21FY25

Over this window: gross 45.1% → 28.6%. Net margin -341.5% is below the sector median.

The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
161,394.0160,005.0154,014.0200,521.0128,304.0130,513.0▲3.9%+5.2%
Cost of revenue
105,879.0114,225.0116,732.0147,741.079,269.071,653.0▼2.1%+12.4%
Gross profit
55,515.045,780.037,282.052,780.049,035.058,860.0▲22.8%−6.1%
Research & development
85,732.097,307.0134,922.0187,170.0193,000.0112,899.0▼27.9%−3.6%
Selling, general & admin
128,013.0141,493.0175,017.0169,818.0160,854.0124,124.0▼19.2%+3.3%
Total operating expenses
186,681.0599,641.0511,595.0387,247.0356,231.0269,295.0▲17.2%+22.2%
Operating incomefeeds ROC rank
−131,166.0−553,861.0−474,313.0−334,467.0−307,196.0−210,435.0▼16.8%—
Other income, net
646.07,803.0164,778.016,308.0−7,052.0−64,437.0——
Pretax income
−130,520.0−546,058.0−309,535.0−318,159.0−314,248.0−274,872.0▼76.4%—
Income tax
713.0318.0316.0−11,424.00.0−93,649.0▲0.6%—
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings
−131,233.0−546,376.0−309,851.0−306,735.0−314,248.0−181,223.0▼76.3%—
Per share
Diluted EPSbuyback-sensitive
−0.40−1.82−1.59−1.21−1.40−0.89▼14.5%—
Diluted shares (mn)
311.25299.96288.37253.63224.55204.14▲4.0%+10.1%
Margins
Gross margin12th pct in Healthcare
34.4%28.6%24.2%26.3%38.2%45.1%▲4.4pp−16.5pp
Operating margin
−81.3%−346.2%−308.0%−166.8%−239.4%−161.2%▼38.2pp−184.9pp
Net margin14th pct in Healthcare
−81.3%−341.5%−201.2%−153.0%−244.9%−138.9%▼140.3pp−202.6pp
† TTM = trailing four quarters through 2026-09-30.FY21 effective tax rate was 34% vs a 0% norm for this window, likely a one-time item; see the filing.
FY09 – FY20 · 12 more years
Unlock the full history →
5 more years of statements and CSV export are on Premium, and 12 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-02-25 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was Pacific Biosciences of California's revenue last fiscal year?

Pacific Biosciences of California reported revenue of $160.0M in fiscal 2025, up 3.9% from fiscal 2024.

What was Pacific Biosciences of California's net income?

Pacific Biosciences of California reported net income of −$546.4M in fiscal 2025, a net margin of −341.5%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.